Hims & Hers: A High-Growth Story, With Real Questions
A fast-growing telehealth disruptor or a risky bet? A deep dive into Hims & Hers through a Buffett and Lynch lens.
Not every fast-growing company is a great investment.
And not every controversial company is a bad one.
Hims & Hers (HIMS) sits right in that tension. It’s one of the fastest-growing consumer health platforms in the market. But it’s also one of the more debated.
This isn’t a stock pick to the Stock Pickz portfolio. It’s a breakdown so you can decide for yourself.
The Business: Simple Idea, Powerful Model
At its core, Hims is a direct-to-consumer telehealth platform.
It sells treatments for things people often don’t want to talk about:
Hair loss
Erectile dysfunction
Mental health
Weight loss
The genius here (a very “Peter Lynch” style thesis) is simplicity. This is not cutting-edge biotech. It’s consumer behavior + convenience.
Instead of doctor visits and pharmacies, Hims offers:
Online consultations
Subscription-based treatments
Recurring delivery
And that last part matters most.
Over 90% of revenue is recurring from subscriptions, creating predictable cash flow and strong retention.
Buffett loves businesses with repeat customers. On the surface, Hims checks that box.
The Growth: Hard to Ignore
Hims is growing fast. Really fast.
2025 revenue: ~$2.35 billion (+59% YoY) (Hims Inc.)
Quarterly growth consistently ~50%+ (Hims Inc.)
~2.5 million subscribers and rising (Hims Inc.)
That’s elite growth for a company at this scale.
Even more interesting: revenue per subscriber is increasing, suggesting pricing power and deeper engagement.
From a Peter Lynch perspective, this is exactly the type of “fast grower” that can outperform, but only if the story holds.
The Bull Case: A Modern Consumer Health Platform
The optimistic view is straightforward:
Hims isn’t just a telehealth company. It’s attempting to become a full-stack healthcare platform.
They’re expanding into:
Hormone therapy
Diagnostics and lab testing
International markets
Personalized medicine
Management is targeting $6.5B+ revenue by 2030. (Hims Inc.)
If they pull this off, Hims could evolve from a niche brand into a dominant consumer health ecosystem.
Think less “online pharmacy” and more “Netflix of healthcare.”
The Concerns: Where the Story Gets Messy
Now let’s shift to the Buffett lens: What could go wrong?
1. Regulatory Risk (Big One)
A large portion of recent growth came from weight-loss drugs (GLP-1s).
But here’s the issue:
Hims sold compounded “knockoff” versions of drugs like semaglutide
Regulators tightened rules once shortages ended
A major partner (Novo Nordisk) cut ties
The result? A sharp stock drop and real uncertainty.
This is critical: If your growth depends on regulatory gray areas, it’s not a moat, it’s a risk.
2. Margin Pressure
Despite strong revenue growth:
Costs are rising faster than revenue
Gross margins are compressing
Heavy investment is required to scale
Buffett avoids businesses that require constant reinvestment just to stay competitive.
Hims may be entering that territory.
3. Brand vs. Moat
Here’s a key question:
What stops competitors from copying this?
Telehealth? Replicable
Subscriptions? Common
Generic medications? Widely available
Hims’ moat is likely:
Branding
Customer acquisition
User experience
Don’t get me wrong, that’s valuable. But it’s not invincible.
4. Valuation vs. Reality
Even after volatility, HIMS has traded at premium multiples vs. peers.
That means expectations are high.
And high expectations + uncertainty is not a combination Buffett typically bets on.
The Verdict: Interesting, But Not Obvious
Hims & Hers is a fascinating company.
On the one hand:
Explosive growth
Recurring revenue
Expanding product ecosystem
On the other:
Regulatory overhang
Margin pressure
Questionable moat
This is not a classic Buffett stock.
But it is the kind of company Peter Lynch might watch closely, especially if growth remains strong and the story becomes clearer.
Final Thought
Hims feels like a company at a crossroads:
It could become a dominant consumer healthcare platform
Or it could prove to be a growth story built on unstable ground
The difference will come down to one thing:
Can it build a durable moat beyond hype-driven growth?
That’s the question worth watching.